{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Berubicin_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "293736-67-1",
    "chebiId": "",
    "chemicalFormula": "C34H35NO11.HCl",
    "definition": "The hydrochloride salt of the anthracycline derivative berubicin with potential antineoplastic activity. Berubicin intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. Unlike other anthracycline derivatives, this agent crosses the blood-brain barrier (BBB).",
    "fdaUniiCode": "7BA3X03948",
    "identifier": "C61568",
    "preferredName": "Berubicin Hydrochloride",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1594"
    ],
    "synonyms": [
      "(8S,10S)-10-((3-amino-4-O-benzyl-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)- 6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione Hydrochloride",
      "BERUBICIN HYDROCHLORIDE",
      "Berubicin Hydrochloride",
      "RTA 744",
      "WP744",
      "topoisomerase II inhibitor RTA 744"
    ]
  }
}